Intra-Cellular Therapies IncChange company Symbol lookupSelect an option...ITCI Intra-Cellular Therapies IncLPRO Open Lending CorpSLGL Sol Gel Technologies LtdUAVS Ageagle Aerial Systems IncIWSY ImageWare Systems IncAMPX Amprius Technologies IncTNC Tennant CoCVX Chevron CorpACGLO Arch Capital Group LtdAAPL Apple IncGo
Intra-Cellular Therapies, Inc. is a biopharmaceutical company. The Company is focused on the discovery, clinical development and commercialization of small molecule drugs that address underserved medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system (CNS). The Company’s product CAPLYTA is a treatment for depressive episodes associated with bipolar I or II disorder (bipolar depression) in adults as monotherapy and as adjunctive therapy with lithium or valproate. The efficacy of CAPLYTA 42 mg in bipolar depression was demonstrated in two positive Phase III placebo-controlled bipolar depression studies, which evaluated the effects of CAPLYTA on depression in adult patients with bipolar I or bipolar II disorder both as monotherapy (Study 404) and as adjunctive therapy with lithium or valproate (Study 402).
|
|
|
|
| |
Company Profile
Intra-Cellular Therapies, Inc. is a biopharmaceutical company. The Company is focused on the discovery, clinical development and commercialization of small molecule drugs that address underserved medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system (CNS). The Company’s product CAPLYTA is a treatment for depressive episodes associated with bipolar I or II disorder (bipolar depression) in adults as monotherapy and as adjunctive therapy with lithium or valproate. The efficacy of CAPLYTA 42 mg in bipolar depression was demonstrated in two positive Phase III placebo-controlled bipolar depression studies, which evaluated the effects of CAPLYTA on depression in adult patients with bipolar I or bipolar II disorder both as monotherapy (Study 404) and as adjunctive therapy with lithium or valproate (Study 402).
Valuation Ratios
- Price/Earnings (TTM)
- --
- Price/Sales (TTM)
- 19.52x
- Price/Book (MRQ)
- 9.64x
- Price/Cash Flow (TTM)
- --
MRQ = Most Recent Quarter
Price Performance
Financial Statements
Balance sheet
Values displayed are in millions.
Income statement
Values displayed are in thousands.
Cash flow
Values displayed are in millions.
Company Officers
- Sharon MatesChmn.
- Lawrence J. HinelineCFO
- Michael I. HalsteadExec.VP
- Suresh K. DurgamExec.VP
- Mark NeumannExec.VP
Address
- 430 East 29Th Street
- New York, NY 10016
- Phone: (646) 440-9333
- Fax: (302) 655-5049
- https://www.intracellulartherapies.com/
Insider Trading
During the most recent quarter, 364K shares were sold in insider trading.
Insider trading information report provided by Copyright © 2023. All rights reserved.
Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.
Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.